IBA Business Update – Third Quarter 2024

Louvain-la-Neuve, Belgium, 21 November 2024- IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its business update for the third quarter ending 30 September 2024.Group OverviewSolid equipment order intake at period-end of EUR 171 million, an increase from last year. Post-period, several major contracts finalized in Industrial Solutions to bring year to date order intake to EUR 215 millionStrong backlog conversion in the third...

Louvain-la-neuve, 21/11/2024 (informazione.it - comunicati stampa - salute e benessere)

- IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its business update for the third quarter ending 30 September 2024.

As previously announced, IBA will begin reporting under new business groupings from 31 December. 'Clinical' will comprise Dosimetry and Proton Therapy, whilst Other Accelerators will become 'Technologies', inclusive of Radiopharmaceutical, Industrial and Engineering & Supply Chain. More details will be shared at the Full Year results in March.

The execution of backlog conversion has continued through the third quarter of the year with this momentum expected to continue for the remainder of the year.

IBA reiterates its mid-term guidance. This guidance is based on the expectation that macro-economic factors will continue to normalize over the coming year. Specifically, it assumes that supply chain issues will stabilize, inflation will decrease to around 3%, and challenges in accessing certain regions will diminish. Additionally, the guidance is contingent on maintaining solid order intake, particularly in the Proton Therapy and Industrial Solutions businesses. As a reminder, given these conditions, IBA anticipates:

***ENDS***

Full Year Results 2024                                                                        20 March 2025

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,000 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

Henri de Romrée       
Deputy Chief Executive Officer
+32 10 475 890
Investorrelations@iba-group.com

Thomas Pevenage
Finance Director
+32 10 475 890
Investorrelations@iba-group.com

Olivier Lechien
Corporate Communication Director
+32 10 475 890
communication@iba-group.com

ICR Healthcare
Amber Fennell, Angela Gray, Lucy Featherstone
+44 (0) 20 3709 5700

IBA@icrhealthcare.com

Proteus ONE is a brand name of Proteus 235

Proteus PLUS is a brand name of Proteus 235

DynamicARC is a registered brand of the IBA's Proton Arc therapy solution currently under development phase.

ConformalFLASH is a registered brand of IBA's Proton FLASH irradiation solution currently under research and development phase

Attachment